Pharma Mar SA (PHMMF) Ratios
Pharma Mar SA Ratios
PHMMF's free cash flow for Q2 2026 was $1.06M. For the 2026 fiscal year, PHMMF's free cash flow was decreased by $-2.31M and operating cash flow was $3.36M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.02 | 3.03 | 2.63 | 2.83 | 3.42 |
| Quick Ratio | 2.48 | 2.41 | 2.22 | 2.54 | 3.30 |
| Cash Ratio | 0.19 | 0.76 | 0.63 | 1.54 | 1.31 |
| Solvency Ratio | 0.58 | 0.23 | 0.05 | 0.32 | 0.52 |
| Operating Cash Flow Ratio | 0.57 | 0.07 | -0.14 | 0.39 | 0.30 |
| Short-Term Operating Cash Flow Coverage | 4.82 | 0.76 | -1.05 | 2.92 | 2.10 |
| Net Current Asset Value | $ 140.17M | $ 108.96M | $ 105.52M | $ 104.88M | $ 104.76M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.15 | 0.13 | 0.11 | 0.13 |
| Debt-to-Equity Ratio | 0.20 | 0.25 | 0.23 | 0.19 | 0.28 |
| Debt-to-Capital Ratio | 0.16 | 0.20 | 0.18 | 0.16 | 0.22 |
| Long-Term Debt-to-Capital Ratio | 0.12 | 0.16 | 0.12 | 0.10 | 0.16 |
| Financial Leverage Ratio | 1.57 | 1.68 | 1.76 | 1.76 | 2.07 |
| Debt Service Coverage Ratio | 4.72 | 3.39 | 0.61 | 3.72 | 6.53 |
| Interest Coverage Ratio | 16.38 | 2.62 | -1.58 | 18.55 | 27.41 |
| Debt to Market Cap | 0.04 | 0.03 | 0.05 | 0.03 | 0.04 |
| Interest Debt Per Share | 3.01 | 3.05 | 2.57 | 2.49 | 2.92 |
| Net Debt to EBITDA | 0.65 | -0.57 | -3.60 | -2.06 | -0.62 |
| Profitability Margins | |||||
| Gross Profit Margin | 94.46% | 95.32% | 93.92% | 93.05% | 92.85% |
| EBIT Margin | 18.19% | 8.27% | -0.76% | 23.51% | 42.86% |
| EBITDA Margin | 21.81% | 12.14% | 2.88% | 26.52% | 45.29% |
| Operating Profit Margin | 18.19% | 3.70% | -2.42% | 22.45% | 40.22% |
| Pretax Profit Margin | 26.94% | 6.85% | -2.29% | 22.30% | 41.39% |
| Net Profit Margin | 33.87% | 14.94% | 0.72% | 25.14% | 40.40% |
| Continuous Operations Profit Margin | 33.87% | 14.94% | 0.72% | 25.14% | 40.40% |
| Net Income Per EBT | 125.71% | 217.98% | -31.38% | 112.71% | 97.61% |
| EBT Per EBIT | 148.11% | 185.30% | 94.67% | 99.36% | 102.90% |
| Return on Assets (ROA) | 18.98% | 7.47% | 0.33% | 12.55% | 25.21% |
| Return on Equity (ROE) | 29.78% | 12.54% | 0.59% | 22.14% | 52.19% |
| Return on Capital Employed (ROCE) | 13.37% | 2.42% | -1.56% | 14.89% | 32.78% |
| Return on Invested Capital (ROIC) | 12.83% | 2.34% | 0.46% | 14.19% | 30.48% |
| Return on Tangible Assets | 19.15% | 7.49% | 0.34% | 12.63% | 25.43% |
| Earnings Yield | 5.82% | 1.87% | 0.15% | 4.25% | 9.01% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.62 | 5.04 | 5.74 | 6.70 | 2.91 |
| Payables Turnover | 0.23 | 0.21 | 0.33 | 0.50 | 0.61 |
| Inventory Turnover | 0.24 | 0.16 | 0.24 | 0.49 | 1.56 |
| Fixed Asset Turnover | 3.68 | 2.96 | 3.32 | 5.66 | 7.51 |
| Asset Turnover | 0.56 | 0.50 | 0.46 | 0.50 | 0.62 |
| Working Capital Turnover Ratio | 1.24 | 1.08 | 0.95 | 1.02 | 1.28 |
| Cash Conversion Cycle | -45.30 | 618.17 | 447.65 | 61.31 | -238.69 |
| Days of Sales Outstanding | 64.97 | 72.39 | 63.59 | 54.51 | 125.31 |
| Days of Inventory Outstanding | 1507.49 | 2269.75 | 1491.78 | 742.52 | 233.96 |
| Days of Payables Outstanding | 1617.76 | 1723.97 | 1107.72 | 735.73 | 597.96 |
| Operating Cycle | 1572.46 | 2342.14 | 1555.37 | 797.04 | 359.28 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 3.09 | 0.34 | -0.75 | 2.12 | 1.42 |
| Free Cash Flow Per Share | 2.54 | -0.54 | -1.64 | 1.63 | 0.99 |
| Dividend Paid and CapEx Coverage Ratio | 2.28 | 0.22 | -0.49 | 1.86 | 1.37 |
| Capital Expenditure Coverage Ratio | 5.66 | 0.39 | -0.84 | 4.33 | 3.29 |
| Operating Cash Flow Coverage Ratio | 1.08 | 0.12 | -0.31 | 0.90 | 0.52 |
| Operating Cash Flow to Sales Ratio | 0.24 | 0.03 | -0.09 | 0.20 | 0.11 |
| Free Cash Flow Yield | 3.39% | -0.68% | -3.89% | 2.54% | 1.73% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 17.42 | 53.56 | 664.68 | 23.52 | 11.10 |
| Price-to-Sales (P/S) Ratio | 5.82 | 8.00 | 4.78 | 5.91 | 4.48 |
| Price-to-Book (P/B) Ratio | 5.12 | 6.72 | 3.91 | 5.21 | 5.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 29.46 | -147.59 | -25.70 | 39.38 | 57.65 |
| Price-to-Operating Cash Flow Ratio | 24.26 | 232.22 | -56.21 | 30.29 | 40.13 |
| Price-to-Earnings Growth (PEG) Ratio | 0.09 | 0.02 | -6.81 | -0.50 | -0.35 |
| Enterprise Value Multiple | 27.34 | 65.37 | 162.54 | 20.23 | 9.28 |
| Enterprise Value | 1.32B | 1.39B | 739.38M | 1.05B | 966.34M |
| EV to EBITDA | 27.34 | 65.37 | 162.54 | 20.23 | 9.28 |
| EV to Sales | 5.97 | 7.93 | 4.68 | 5.37 | 4.20 |
| EV to Free Cash Flow | 30.19 | -146.31 | -25.15 | 35.75 | 54.06 |
| EV to Operating Cash Flow | 24.86 | 230.21 | -54.99 | 27.49 | 37.63 |
| Tangible Book Value Per Share | 14.43 | 11.82 | 10.70 | 12.21 | 9.67 |
| Shareholders’ Equity Per Share | 14.63 | 11.88 | 10.81 | 12.35 | 9.85 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.26 | -1.18 | 1.31 | -0.13 | 0.02 |
| Revenue Per Share | 12.86 | 9.97 | 8.84 | 10.88 | 12.72 |
| Net Income Per Share | 4.36 | 1.49 | 0.06 | 2.73 | 5.14 |
| Tax Burden | 1.26 | 2.18 | -0.31 | 1.13 | 0.98 |
| Interest Burden | 1.48 | 0.83 | 3.00 | 0.95 | 0.97 |
| Research & Development to Revenue | 0.43 | 0.59 | 0.63 | 0.43 | 0.31 |
| SG&A to Revenue | -0.01 | -0.02 | 0.12 | 0.10 | 0.08 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.89 | 0.50 | -11.83 | 0.88 | 0.27 |
Currency in EUR